ArticleOncotarget2020

Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors.

Michael R Mortensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.